This is a transformative, high-upside entry into the New York cannabis market with a capital-efficient structure that limits balance sheet risk. The key catalysts are the execution of definitive purchase agreements (expected within 4 weeks) and regulatory approval. Monitor for the final purchase agreement and any updates on the Section 280E assumption, which is critical to the cash flow projections. The 7% potential dilution from the preferred conversion is manageable given the scale of the opportunity.
Price Chart
Executive Summary
Grown Rogue International Inc. (GRUSF) filed an 8-K detailing the initial steps toward the planned acquisition of PharmaCann Inc.'s New York license and assets. The company formed a joint venture, Grown Rogue New York LLC (GRNY), with a capital partner who provided $10 million for a 49% preferred equity stake and committed an additional $5 million drawable term loan. GRNY has entered into interim operating, lease, and loan agreements to manage and fund PCNY's operations, including four Verilife dispensaries and a cultivation facility, while definitive purchase agreements are finalized. The purchase price is anticipated to be approximately $4.5 million, with $3 million payable upon regulatory approval, and the company expects the New York operations to become cash flow positive within nine months and generate ~$600k in monthly cash flow within 18 months, though this is heavily dependent on lease adjustments and the non-applicability of Section 280E.
Key Financial Metrics
Key Facts
- Grown Rogue formed a 51/49 JV (GRNY) with a capital partner to acquire PharmaCann's NY license and assets.
- Capital partner invested $10M for a 49% preferred equity stake in GRNY, convertible into ~18.2M GRUSF shares (~7% dilution) at $0.55/share.
- Capital partner committed an additional $5M drawable term loan at 15% interest.
- Anticipated purchase price for PCNY is ~$4.5M, with $3M payable upon regulatory approval.
- GRNY entered into a GSA, master lease, and up to $9M secured loan to manage and fund PCNY's operations during the transition.
- PCNY's four Verilife dispensaries averaged $1.7-2.0M in monthly sales; the Hamptonburgh facility produced >2,000 lbs of flower/month before slowing.
- Company expects NY operations to become after-tax cash flow positive within 9 months and generate ~$600k/month within 18 months.
- Identified cost savings of ~$20M annually, with >75% from lease adjustments; cash flow expectations assume Section 280E is no longer applicable by 2027.
Financial Impact
Total project-based financing of $15M ($10M equity + $5M debt) to fund a ~$4.5M acquisition and ~$12M in total project costs. Anticipated annual cost savings of ~$20M and monthly cash flow of ~$600k within 18 months.
Risk Factors
- Failure to execute definitive purchase agreements or obtain regulatory approvals.
- Operational ramp at Hamptonburgh facility may take longer or cost more than expected (6-9 month ramp).
- Cash flow projections are heavily dependent on lease renegotiations (>75% of savings) and the assumption that Section 280E will no longer apply by 2027.
- Potential disruption to dispensary sales during the transition due to reduced first-party product availability.
- Dilution risk from conversion of preferred equity (~7%) and warrants (0.901 per $1 drawn on term loan).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001279569-26-000827 |
| Document: 0001279569-26-000827-index.html | 0001279569-26-000827 |
| Document: 0001279569-26-000827.txt | 0001279569-26-000827 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $0.3500 | awaiting T+1 | — | $0.3500 (−0.00%) |
Oct 20, 2026 5d ago | 8-K | $0.3700 $0.3500 | ▼ −5.41% | ▼ −4.22% | $0.3500 (−5.41%) |
Oct 20, 2026 6d ago | 8-K | $0.3700 $0.3700 | · 0.00% | ▼ −0.53% | $0.3500 (−5.41%) |
Aug 25, 2026 8w ago | 8-K | $0.4700 $0.4601 | ▼ −2.11% | ▼ −2.13% | $0.3500 (−25.53%) |
May 1, 2026 25w ago | 10-K/A | $0.3600 $0.3700 | ▲ +2.78% | ▲ +1.98% | $0.3500 (−2.78%) |
Apr 27, 2026 26w ago | 8-K | $0.3800 $0.3800 | · 0.00% | ▲ +0.49% | $0.3500 (−7.89%) |
Apr 7, 2026 28w ago | 8-K | $0.2900 $0.2700 | ▼ −6.90% | ▼ −7.47% | $0.3500 (+20.69%) |
Mar 18, 2026 31w ago | 8-K | $0.3200 $0.3000 | ▼ −6.25% | ▼ −4.51% | $0.3500 (+9.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers